and XXXX today quarter all joining financial us you, results. second for Harold, our discuss to you thank Thank
companies. quarter be we to earlier the like President stepping Executive Before of discussing Mike AxoGen growth the a Michael announced next and leading Dale Heart is life building X, his extensive I retire. served and recently to will Officer. stage AxoGen's would as as equipped successfully history experience, well Effective to science Abbott's I and innovation has today, as in phase Michael August AxoGen. Structural With long Mike lead and of scaling welcome Chief commercial of as its through
a with had to and launch major pleased Avance number We're positive achieving second the growth, our milestones. of now trends quarter. Tissue quarter Nerve our Soft solid Turning submission for of and line BLA the in performance the Matrix progress Avive-plus revenue Graft. a We of bottom
positive growth making cash we Our driving achievements towards profitability, highlight generating and reaching flow. strides towards our are the targets,
$X.X revenue across million to we've products was our $XX.X was today's and growth. growth applications. Notably, review an will loss top pleased across $X.X the last of business. million, During was and a broad-based call, increase I versus EBITDA Revenue revenue million line adjusted advancements accomplishments XX.X% our and year. We're year, the quarter's with compared while EBITDA of made last our
growth execution our of productivity and this results our solid were commercial improved During by driven strategy. sales quarter,
focused Our strategy in presence on our remains high potential accounts. deepening
microsurgeons. hospitals Specifically, Level high X number academic-affiliated trained trauma centers a with and of
of accounts applications. nerve business targeted within the repair to is all across continue these goal our Our repair penetrate nerve to
in shift million. from QX our execution approximately the early our strong QX. as saw and quarter, to for earnings in $X.X we in quarter, a impacted this shift mentioned March this results We believe procedures positively addition some call, to the In we
strong As this detail In XXX year. and our will quarter, our the of and the in end guidance a first in of Core of of moments. full XXX the prior result second the at Accounts we end revenue XXX our more of year, Nir of momentum quarter for the to a provide half quarter performance increased year, and the the few are raising the year versus this at first
Accounts are trailing months $XXX,XXX than Core revenue As revenue. more a our generating and total in XX over those XX% represent of defined the reminder, currently as approximately
in an increase $X and to of and Accounts second sequentially, to add direct as continue largest the and primarily reps will growth X our quarter Our million driven needed. productivity reps We over evaluate a believe with be additional Core ago. our by XXX year force, of annualized ended we We sales. revenue will representatives, increased are sales sales sales compared
agencies our represent XX% that revenue. Our of supplemented is sales independent direct approximately total sales force by
the programs we breast procedure, the in the and portfolio, reconstructive providing the our surgeon incorporate and programs in for repair continue their to in surgical market, a is education education surgeon-led interest products innovations implant-based leader teams advanced We are the return to complete repair completed nerve our implant-based breast to key additional two this completed team new and on track prepare to re-sensation pleased new the the are training the in of announced of technique which sensation quarter. surgical neurotization. breast. neurotization two in an we've from expanded surgeons We're nerve additional surgeons the new protection to third for response both innovation a of included As pillar year the In strategy. new re-sensation with immersive re-sensation the products three reconstruction. the and breast opportunity program, training growth driving program through for their procedure into patient the These see an space. and previously to and breast and quarter, provide applications patients strong nerve solutions We
our injuries. injuries, the we and but nerve nerve these have nerve the compression, healing. a injuries who opportunity a part tissue multiple which We've surgeons protection after structure we with nerve work including our education complex still expanded we procedure. and nerve and The to support on programs, damage non-transected as for mastectomy are We're connecting awareness patient protection number continue AxoGen, with for impact right to have diverse significant drives wide intact, reconstructive crush of the nerves. during above solutions a quality address nerve advocacy estimate focus breast neurotization a driving invest to groups of need injured surrounding of education is also a website. million, to represents diverse category to of pleased opportunity their which and perform range We addition the and neurotization for the growth defects, on phase the mastectomy. to the traumatic protecting nerve The potential surgeon In our build of its injuries. with market, could patients market need of increasing awareness patient patients $XXX bed, breast who critical see internal covers of life of in of of injuries receive through recent types innovation to numbness protecting and In or these
Our Nerve surgeons by HA-plus be driver. to portfolio Protector, well and which category received important continues in first addition AxoGuard growth the an protection was nerve
a tissue nerve offerings our is as of expand tissue protection. Soft we and to our Avive-plus soft barrier Matrix. continuing peripheral amniotic allograft June phase critical provides in the newest separation protection use is announced Avive-plus and We're And intended membrane full a re-absorbable of that nerve the XXXX, for temporary healing. of product, launch Tissue during for multilayer
will with multiple nerve use cases that repair surgeon positive initial and We are we applications. pleased in believe the feedback, have Avive-plus
the the With addresses diverse protection offer we portfolio repair, for these most market. nerve additions, believe protection in we the needs comprehensive which
growing our Moving on clinical evidence. to body of updates on
made the develop utility quality clinical to repair safety, performance, solutions. significant years, evidence we've demonstrate the economics and health to our nerve Over care of investments
expected. programs are progressing clinical active as Our
in peer-reviewed This end The level titled: techniques. Peripheral July Plastic a those of Direct more Nerve coaptation patients and connector-assisted evaluating Repair nerves direct had and Comparative Using trauma, pain. Repair published and of the study repair XXXX, experienced the in Systematic Global Effectiveness, repair quarter, the Open. intolerance repair breast, significantly of patients fewer Reconstructive than new and evidence that A Connector-Assisted differences In between repaired approaches of we outcomes found with repair Review including of assessed Journal applications the Repair As the Surgery OMF X connector-assisted cold in suture-only achieved in Meta-Analysis recovery and study, XXX significantly and was had group. publications, group meaningful nerve direct
meta-analysis methods. repair protecting coaptation is historical AxoGuard implants standard alone. a benefit surgeon A decision-making to for believe we role an like for repair transected important of suture-direct common the will and repair and that of with evidence in nerve play findings direct the is the repair the one Similar most nerve as techniques nerves. and protectors care connectors of previously in gap of to supports nerve clinical site compared our published connector-assisted adoption these repair, considered This
this allow mid-XXXX. the we a BLA modules line milestone We the completed the for plan in excited to data believe remaining We're the with first to for in to Nerve We important in third submission Turning FDA of approval provide Graft. an wave time will the that Avance May. potential of quarter. submission
As BLA will to XXX approval a Avance Nerve a biological transition reminder, a to product. process regulatory Graft the complete
from be reference product least XX exclusivity market biosimilars, Avance providing the as years believe designated will of approval date. we at the potential Importantly, for
the the in showcasing our leaders creating processing not only new capabilities This strong this had event processing AxoGen all of underscores economy. to our we center demonstrates transitioned a It XXXX, celebrated capacity, the quality innovation. key our enhances of near to to transition And esteemed the to fully XXXX, ribbon-cutting and dedication we biologic official processing community center construction also investment component jobs supported local many was high-quality our community, By fostering of leaders. Ohio. it Dayton, new relationships our our commitment this by Another to and facility. and of advanced and regional but validation June end with in local and contributing new
the As near start-up a were gross we margin in have magnitude new term. incurred our of often costs impacted in have that we ramp-up some and expected initially seen greater facilities, than the
confident forward. have we're challenges, these moving and We resolved in to our ability early execute
operating this start-up state-of-the-art some we've insight running During the of also facility. into gained process, incremental biologics costs
improvements to We other higher that capacity see costs will and expect offset these help utilization time. over
conclusion, pleased the which and execution results, our with commitment growth reflect quarter innovation. to strategy of successful we're strong second In our
provide will revenue delivering the our Looking profitability, financial growth of revolutionize Nir, the to mission focused guidance further our the Nir? nerve and call full on and we advance now details on ahead, over for XXXX. provide updated on to we remain who hand science I'll our as year the repair. financials
